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Trials of anti-tumour necrosis factor therapy for COVID-19 
are urgently needed
With more than 81 000 deaths worldwide from 
coronavirus disease 2019 (COVID-19) by April 8, 2020,1 
it is incumbent on researchers to accelerate clinical trials 
of any readily available and potentially acceptably safe 
therapies that could reduce the rising death toll. Severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
gains access to host cells via angiotensin-converting 
enzyme 2, which is expressed in the type II surfactant-
secreting alveolar cells of the lungs.2 Severe COVID-19 is 
associated with a major immune inflammatory response 
with abundant neutrophils, lymphocytes, macrophages, 
and immune mediators. Which mediators are most 
important in driving the immune pathology remains to 
be elucidated. Deaths from COVID-19 are chiefly due to 
diffuse alveolar damage with pulmonary oedema, hyaline 
membrane formation, and interstitial mononuclear 
inflammatory infiltrate compatible with early-phase adult 
respiratory distress syndrome (ARDS).3 Prevention of 
ARDS and death in patients with COVID-19 is a pressing 
health emergency.
Anti-tumour necrosis factor (TNF) antibodies have been 
used for more than 20 years in severe cases of autoimmune 
inflammatory disease such as rheumatoid arthritis, inflam-
matory bowel disease, or ankylosing spondylitis. There 
are ten (as reported on Sept 29, 2019) US Food and Drug 
Administration approved and four off-label indications 
for anti-TNF therapy,4 indicating that TNF is a valid target 
in many inflammatory diseases. TNF is present in blood 
and disease tissues of patients with COVID-195 and TNF 
is important in nearly all acute inflammatory reactions, 
acting as an amplifier of inflammation. We propose that 
anti-TNF therapy should be evaluated in patients with 
COVID-19 on hospital admission to prevent progression 
to needing intensive care support.
There is evidence of an inflammatory excess in patients 
with COVID-19. Lung pathology in COVID-19 is charac-
terised by capillary leakage of fluid and recruitment of 
immune-inflammatory lymphocytes, neutrophils, and 
macrophages,6 implying a role for adhesion molecules, 
chemokines, and cytokines targeting vascular endothelium.
Cytokine upregulation is documented in COVID-19. 
In patients with COVID-19, there is upregulation of 
pro-inflammatory cytokines in the blood, including 
interleukin (IL)-1, IL-6, TNF, and interferon γ,7,8 
and patients in intensive care units have increased 
concentrations of many cytokines. Preliminary data from 
Salford Royal Hospital and the University of Manchester 
in the UK document the presence of proliferating excess 
monocytes expressing TNF by intracellular staining in 
patients with COVID-19 in intensive care (Hussell T, 
Grainger J, Menon M, Mann E, University of Manchester, 
Manchester, UK, personal communication). Available 
cytokine data on immunology and inflammation in 
COVID-19 are summarised in the appendix.
Initial reports comprising a trial of 21 severe and critical 
COVID-19 patients in China (ChiCTR2000029765) and 
a case study from France9 of clinical benefit with the 
anti-IL6 receptor antibody10 tocilizumab in COVID-19 
suggest that cytokines are of importance in the “cytokine 
storm” and further controlled clinical trials are in progress. 
Although there are many potential drug candidates for 
reducing inflammation in COVID-19, only a few drugs 
such as the anti-TNF antibodies infliximab or adalimumab 
are potentially effective, widely available, and have a 
well established safety profile.
The potential role of anti-TNF therapy thus warrants 
consideration. Preclinical studies suggest that the response 
to severe respiratory syncytial virus (RSV) and influenza in 
mice is ameliorated by anti-TNF therapy, which reduces 
weight loss, disease duration, and cell and fluid infiltrate.11 
This research suggests a potential rationale for use of 
anti-TNF therapy in viral pneumonia, especially given 
the known mechanism of action of TNF and the reversal 
of TNF-induced immunopathology by TNF blockade in 
multiple diseases. It is known TNF is produced in most 
types of inflammation, especially in the acute phase, and 
is important in the coordination and development of the 
inflammatory response. However, too much production of 
TNF for too long becomes immune suppressive.12 Blockade 
of TNF alone is clinically effective in many circumstances 
and diseases, despite the presence of many other pro-
inflammatory cytokines and mediators. There is evidence 
of a “TNF dependent cytokine cascade” in rheumatoid 
arthritis tissue and upon bacterial challenge in baboons.13,14 
Thus, if TNF is blocked, there is a rapid (ie, <12 h) decrease 
of IL-6 and IL-1 concentrations in patients with active 
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rheumatoid arthritis15 and, importantly, a reduction of 
adhesion molecules and vascular endothelial growth 
factor, which is also known as vascular permeability factor, 
denoting its importance in capillary leak.15–19 Furthermore, 
a reduction in leucocyte trafficking occurs in inflamed 
tissues of joints due to reduction in adhesion molecules 
and chemokines20 with reduction in cell content and 
exudate. Finally, after anti-TNF infusion tissue TNF is 
reduced as it passes into the blood bound to the anti-TNF 
antibody. Blood concentrations of immunoreactive, but 
biologically inactive, TNF increase more than ten times 
after infusion.15 For these reasons it is possible that a single 
infusion of anti-TNF antibody might reduce some of the 
processes that occur during COVID-19 lung inflammation, 
reducing TNF and other inflammatory mediators, 
cellularity, and exudate.
What would be the best time for intervention with anti-
TNF therapy in patients with COVID-19? We postulate 
that the earlier the better after hospital admission might 
be the answer because patients will already have initiated 
anti-viral immunity for several days. There is a balance 
to be struck between stage of intervention and ensuring 
patients are at sufficient risk of a poor outcome and can 
be appropriately monitored. We propose that initial 
assessment of anti-TNF therapy in clinical trials should be 
in patients with moderate disease admitted to hospital 
and who require oxygen support but not intensive care. 
If this treatment approach proved beneficial with a good 
safety profile, treatment in the community for people 
identified as being at high risk of progressing to hospital 
admission might be considered. The range of available 
formulations and administration routes of anti-TNF 
products could facilitate this treatment approach.
Is there a trade-off between immunity and virus 
clearance? The use of powerful anti-inflammatory drugs 
in acute viral diseases has to be approached with caution 
because of the risk of increasing viral replication or 
bacterial infections. For lung viral infections, the higher 
the infectious dose, the greater the tissue damage from 
viral replication and the ensuing immune response. 
In animal models that resemble lung viral infection in 
humans, the immune response to the virus is so great 
that even a moderate reduction in inflammation is 
beneficial—eg, mice with severe pneumonia from RSV 
or influenza benefit from anti-TNF treatment without 
compromising viral clearance11 because more of the lung 
architecture is preserved.
However, concerns about safety are important when 
considering new therapy. Would anti-TNF therapy increase 
the risk of bacterial or fungal super-infections? After 
respiratory viral infection, superinfections with other 
organisms occur at the most severe end of the disease 
spectrum. Many research groups have elucidated the 
mechanisms responsible21 and anecdotal evidence suggests 
that bacteria might have a role in in COVID-19,5,22 although 
this remains to be confirmed. Bacteria gain a foothold 
faster in a lung that is damaged. Experimental studies 
suggest that if the duration of inflammation is limited, 
with its associated collateral lung damage, then bacterial 
superinfection is reduced.23 There is concern that anti-TNF 
therapy might increase the risk of bacterial infection.24 
Yet two randomised studies in critically unwell patients 
with septic shock25,26 showed that monoclonal anti-TNF 
therapy had good safety data with no evidence of increased 
secondary bacterial infections in the anti-TNF treated 
group. In an observational trial in rheumatoid arthritis 
patients with serious infections, the risk of sepsis and death 
was reduced in patients on TNF inhibitors compared with 
those on synthetic disease-modifying anti-rheumatic 
drugs (DMARDS).27 46 (11%) of 399 patients on TNF 
inhibitors developed sepsis after serious infection, of whom 
20 (43%) died, compared with 74 (17%) of 444 patients on 
DMARDS who developed sepsis, of whom 54 (74%) died.27 
Paradoxically, another class of TNF inhibitor, a TNF-R2 
Ig-Fc fusion protein, etanercept, was associated with 
moderately increased mortality in a randomised trial of 
this treatment for sepsis,28 possibly due to its faster off-rate 
for TNF potentially resulting in some redistribution and 
bioavailability of pathogenic TNF rather than its clearance.
There has been interest as to whether the safety of anti-
TNF therapy in patients with COVID-19 might be gleaned 
from analysis of the course of COVID-19 in patients with 
inflammatory bowel disease (IBD) or rheumatoid arthritis 
who are already on anti-TNF treatment. As of April 6, 2020, 
on SECURE-IBD, a coronavirus and IBD reporting database 
with a register of outcomes of IBD patients with 
COVID-19, there were 116 patients on anti-TNF therapy 
alone, 99 of whom recovered without hospitalisation and 
one patient died. By contrast, about half of 71 patients 
on sulfasalazine/mesalamine recovered without hospital 
admission and six patients died. Thus IBD patients with 
COVID-19 on anti-TNF therapy do not fare worse than 
those treated with other drugs, but there are insufficient 
data to make conclusions about a better outcome.
For SECURE-IBD see https://
covidibd.org/
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We believe there is sufficient evidence to support clinical 
trials of anti-TNF therapy in patients with COVID-19. With 
an average of 2 days between hospital admission and 
ARDS,7 we propose anti-TNF therapy should be initiated 
as early as is practicable. If there is preliminary evidence 
of benefit and safety of anti-TNF therapy in hospitalised 
patients, we suggest consideration should be given to 
out of hospital treatment for patients with COVID-19 at 
high risk, such as older people and those with pre-existing 
conditions, and who can be monitored appropriately.
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